AZD2461 Cas 1174043-16-3 PARP Inhibitors

AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted to see how it may work to treat solid tumors. The main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.

Related Prodcuts:

Etoposide; Etoposide phosphate; ML-323; BMH-21; Nexturastat A; TMP269; GSK2606414; ELR510444; Chidamide; Inauhzin; CW069; Purvalanol A; Purvalanol B; JW55; Tenovin-6; Tenovin-6 HCL; RKI-1447; Tasquinimod

[1]. Oplustil O'Connor L, et al. The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.

[2]. Węsierska-Gądek J, et al. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. J Cell Biochem. 2015 Dec;116(12):2824-39.